Heart drug vericiguat under the microscope: Real-World results from 500 patients
NCT ID NCT06486844
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This study looked at data from 500 people in Germany who were prescribed vericiguat for chronic heart failure with reduced ejection fraction (a weak heart). Researchers wanted to see how well the drug works in everyday medical care, not just in a controlled trial. They measured death rates and hospital visits related to heart failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bayer
Wuppertal, 42096, Germany
Conditions
Explore the condition pages connected to this study.